Travere Therapeutics
TVTX
171 hedge funds and large institutions have $1.72B invested in Travere Therapeutics in 2022 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 63 increasing their positions, 56 reducing their positions, and 23 closing their positions.
276% more call options, than puts
Call options by funds: $9.19M | Put options by funds: $2.44M
13% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 56
4% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 23
2% more capital invested
Capital invested by funds: $1.68B → $1.72B (+$34M)
0% more funds holding
Funds holding: 171 → 171 (0)
0.4% less ownership
Funds ownership: 109.46% → 109.05% (-0.4%)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$13.3M |
| 2 |
O
OrbiMed
New York
|
+$12.4M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$11.5M |
| 4 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$11.5M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$41.5M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$21.1M |
| 3 |
PA
Perceptive Advisors
New York
|
-$12.4M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$9.26M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$8.63M |
TVTX Hedge Fund Activity: Q3 2022 in Review
171 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q3 2022, worth a combined $1.72B — up 2% from $1.68B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new TVTX positions and 23 closed out — a net gain of 1 holder — while 63 added to existing stakes and 56 trimmed.
The largest buyer was Armistice Capital, adding an estimated $13.3M. The largest seller was VR Adviser, exiting entirely with an estimated $41.5M sold.
- 171 institutional investors held Travere Therapeutics (TVTX) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $1.72B of Travere Therapeutics stock for Q3 2022, up 2% quarter-over-quarter.
- 24 funds opened new Travere Therapeutics positions in Q3 2022 and 23 closed out, a net change of +1 holder.
- The largest Travere Therapeutics buyer in Q3 2022 was Armistice Capital, an estimated $13.3M added.
- The largest Travere Therapeutics seller in Q3 2022 was VR Adviser, an estimated $41.5M sold.
Based on aggregated 13F filings for Q3 2022.